Education
About Us
Working with TipRanks
Follow Us
Nrx Pharmaceuticals, Inc. (NRXP)
:NRXP
Total Valuation
NRX Pharmaceuticals has a market cap or net worth of $51.49M. The enterprise value is $36.49M.
Market Cap$51.49M
Enterprise Value$36.49M
Share Statistics
NRX Pharmaceuticals has 19,503,412 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,503,412
Owned by Insiders7.78%
Owned by Institutions7.59%
Financial Efficiency
NRX Pharmaceuticals’s return on equity (ROE) is 1.08 and return on invested capital (ROIC) is 111.15%.
Return on Equity (ROE)1.08
Return on Assets (ROA)-6.88
Return on Invested Capital (ROIC)111.15%
Return on Capital Employed (ROCE)1.02
Revenue Per Employee0.00
Profits Per Employee-12.56M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NRX Pharmaceuticals is ―. NRX Pharmaceuticals’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value-1.00
Price to FCF0.00
Price to Operating Cash Flow-4.22
PEG Ratio―
Income Statement
In the last 12 months, NRX Pharmaceuticals had revenue of 0.00 and earned -25.13M in profits. Earnings per share was -2.39.
Revenue0.00
Gross Profit0.00
Operating Income-18.50M
Pretax Income-25.13M
Net Income-25.13M
EBITDA-18.50M
Earnings Per Share (EPS)-2.39
Cash Flow
In the last 12 months, operating cash flow was -135.81K and capital expenditures 0.00, giving a free cash flow of -135.81K billion.
Operating Cash Flow-135.81K
Free Cash Flow-135.81K
Free Cash Flow per Share>-0.01
Dividends & Yields
NRX Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.03
52-Week Price Change27.54%
50-Day Moving Average3.09
200-Day Moving Average2.35
Relative Strength Index (RSI)34.10
Average Volume (3m)151.28K
Important Dates
NRX Pharmaceuticals upcoming earnings date is Aug 18, 2025, Before Open (Confirmed).
Last Earnings DateMay 15, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
NRX Pharmaceuticals as a current ratio of 0.15, with Debt / Equity ratio of 0.00%
Current Ratio0.15
Quick Ratio0.15
Debt to Market Cap0.28
Net Debt to EBITDA-0.28
Interest Coverage Ratio-80.44
Taxes
In the past 12 months, NRX Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NRX Pharmaceuticals EV to EBITDA ratio is -1.53, with an EV/FCF ratio of -2.66.
EV to Sales0.00
EV to EBITDA-1.53
EV to Free Cash Flow-2.66
EV to Operating Cash Flow-2.66
Balance Sheet
NRX Pharmaceuticals has $5.55M in cash and marketable securities with $8.40M in debt, giving a net cash position of $2.85M billion.
Cash & Marketable Securities$5.55M
Total Debt$8.40M
Net Cash$2.85M
Net Cash Per Share$0.15
Tangible Book Value Per Share-$2.21
Margins
Gross margin is 25.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin25.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for NRX Pharmaceuticals is $18.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$18.00
Price Target Upside581.82% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast41.01%